Saturday, February 26, 2011

Learning How to Communicate with Someone Suffering From Alzheimer's Disease

As I thought about this I came to a simple conclusion. Instead of trying to change Alzheimer's World, instead of trying to fight Alzheimer's World, not only would I accept Alzheimer's World as a reality, I would go into Alzheimer's World and learn how to communicate effectively...

By Bob DeMarco
Alzheimer's Reading Room

Earlier today, Carole Larkin published an interesting article -- How the Loss of Memory Works in Alzheimer’s Disease, and How Understanding This Could Help You.

The article described in layman's terms how problems with short term memory are directly related to the region of the brain known as the hippocampus; and, how when this brain region stops functioning properly a person losses their ability to store information.

Continue reading at the Alzheimer's Reading Room

Read More on the Alzheimer's Reading Room

Wednesday, January 06, 2010

Communication in Alzheimer's World

Let's face it, dealing with Alzheimer's is not easy. Understanding Alzheimer's disease is not easy. Some people can't do it...ever...
By Bob DeMarco

It takes a lot of energy, learning, and patience to deal with the Alzheimer's disease.

In order to begin the process of dealing with communication in a world fill with Alzheimer's you first need to make a simple important decision -- you want to decrease both your stress as caregiver, and the stress of the person suffering from Alzheimer's.

Read that carefully, you want to reduce stress. You want to change the dynamic. You want to change for the better -- you want and need to change the way things are.

You might be wondering why I just repeated myself. Why? Because I believe it is necessary to get focused on what you want to accomplish, if you ever expect to accomplish it. It must become a deep and strong desire within you.

To continue reading go here.

Popular articles on the Alzheimer's Reading Room

Bob DeMarco is the editor of the Alzheimer's Reading Room and an Alzheimer's caregiver. The Alzheimer's Reading Room is the number one website on the Internet for news, advice, and insight into Alzheimer's disease. Bob has written more than 950 articles with more than 8,000 links on the Internet. Bob resides in Delray Beach, FL.
The Alzheimer's Action Plan: The Experts' Guide to the Best Diagnosis and Treatment for Memory Problems

Original content Bob DeMarco, Alzheimer's Reading Room

Friday, August 31, 2007

Magnetoencephalography (MEG)

This development has wonderful implications for diagnosing Alzheimer's; it has far reaching implications for those predisposed by genetics to Alzheimer's disease.

Read this article at the Alzheimer's Reading Room

Wednesday, April 18, 2007

Robert T DeMarco Weblog: CNBC Portfolio Challenge Bonus Bucks Answers

CNBC Portfolio Challenge Bonus Bucks Answers for Wednesday, April 18, 2007 and CNBC Million Dollar Portfolio Challenge

According to the Mortgage Bankers Association, borrowing costs on 30-year fixed-rate mortgages averaged how much last week?

The European Patent Forum kicks off today in which major European city?

Get the Answers

Friday, March 30, 2007

CNBC Million Dollar Portfolio Challenge

CNBC Portfolio Challenge Bonus Bucks Answers for Friday, March 30, 2007 and CNBC Million Dollar Portfolio Challenge

How many new stores did Home Depot open in the U.S. in 2006?
The FDA-approved drug Provenge is used to fight what disease?

Get the Answers

Thursday, December 28, 2006

Announcing CareGiver: The Book

I started a new Weblog that is devoted to my Caregiving activites. Caregiver the Book contains a table of contents and is written in the form of a book.

The blog contains a description of the trials, tribulations and wonder of dealing with an Alzheimer's patient, my 90 year old mother. The blog contains our story.


Saturday, December 23, 2006

Robert T DeMarco

You can read the articles on this blog plus all the posts from all my blogs at the Robert T DeMarco  Weblog.

Saturday, November 18, 2006

The CareGiver: Huperzine A Factsheet (Alzheimer's)

I recently read about Huperzine A. The following page contains a fact sheet about the herb. Huperzine A may have cognition-enhancing activity in some.

Source Huperzine A


Huperzine A is available from numerous manufacturers generically. Branded products include Memorall (PharmAssure), Huperzine Rx-Brain (Nature's Plus).


Huperzine A is a plant alkaloid derived from the Chinese club moss plant, Huperzia serrata, which is a member of the Lycopodium species. Huperzia serrata has been used in Chinese folk medicine for the treatment of fevers and inflammation.

Huperzine A has been found to have acetylcholinesterase activity. Huperzine B, also derived from Huperzia serrata, is a much less potent acetylcholinesterase inhibitor. Natural huperzine A is a chiral molecule also called L-huperzine A or (-)-huperzine A. Synthetic huperzine A is a racemic mixture called (±)-huperzine A. Huperzine A is also known as HUP, hup A and selagine. In Chinese medicine, the extract of Huperzia serrata is known as Chien Tseng Ta and shuangyiping. Huperzine A derivatives are being developed for pharmaceutical application.


Huperzine A may have cognition-enhancing activity in some.


Alzheimer's disease is a neurodegenerative disorder associated with neuritic plaques that affect the cerebral cortex, amygdala and hippocampus. There is also neurotransmission damage in the brain. One of the major functional deficits in Alzheimer's disease is a hypofunction of cholinergic neurons. This leads to the cholinergic hypothesis of Alzheimer's disease and the rationale for strategies to increase acetylcholine in the brains of Alzheimer's disease patients. Two FDA-approved drugs for the treatment of Alzheimer's disease, tacrine and donepezil, are acetylcholinesterase inhibitors.

Huperzine A is also an acetylcholinesterase inhibitor and has been found to increase acetylcholine levels in the rat brain following its administration. It also increases norepinephrine and dopamine, but not serotonin levels. The natural L or (-)-huperzine A is approximately three times more potent than the racemic or (±)-huperzine A in vitro.


There are limited pharmacokinetic studies with huperzine A. It appears that huperzine A is rapidly absorbed from the gastrointestinal tract and transported to the liver via the portal circulation. Some first-pass metabolism takes place in the liver, and huperzine A and its metabolites are distributed widely in the body, including to the brain. Following ingestion, the time to reach peak blood level is approximately 80 minutes.


Huperzine A has potent pharmacological effects and, particularly since long-term safety has not been determined, it should only be used with medical supervision. It may have some effectiveness in Alzheimer's disease and age-related memory impairment. It has been used to treat fever and some inflammatory disorders, but there is no credible scientific evidence to support these uses.


Numerous studies, most of them from China, suggest that huperzine A may be as effective as the drugs tacrine and donepezil in Alzheimer's disease. This is not so surprising since in vitro and animal model tests have demonstrated that huperzine A effectively inhibits acetylcholinesterase, an enzyme that catalyzes acetylcholine breakdown. Tacrine and donepezil work in the same way to conserve acetylcholine in the brain--the mode by which they presumptively improve memory and cognition in those with Alzheimer's and age-related cognitive impairment. Huperzine A may prove superior to tacrine (dose-limited due to its hepatotoxicity) if long-range studies, yet to be conducted, demonstrate its safety.

In one double-blind, randomized study, huperzine A, in injectable form, was tested against a saline control in 56 patients with multi-infarct dementia or senile dementia and in 104 patients with senile and pre-senile simple memory disorders. Huperzine A produced significant positive effects as measured by the Wechsler Memory Scale. Dizziness was experienced by a few of the huperzine A-treated patients.

In another study, this one multicenter, double-blind, placebo-controlled and randomized, 50 subjects with Alzheimer's disease were given huperzine A or placebo for eight weeks. Significant improvement was noted in 58 percent of the patients in terms of memory, cognitive and behavioral functions. Research is ongoing.


None known.


Huperzine A should be avoided by children, pregnant women and nursing mothers.

Because of possible adverse effects in those with seizure disorders, cardiac arrhythmias and asthma, those with these disorders should avoid huperzine A. Those with irritable bowel disease, inflammatory bowel disease and malabsorption syndromes should avoid huperzine A.


Adverse effects reported with huperzine A include gastrointestinal effects, such as nausea and diarrhea, sweating, blurred vision, fasciculations and dizziness. Possible adverse effects include vomiting, cramping, bronchospasm, bradycardia, arrhythmias, seizures, urinary incontinence, increased urination and hypersalivation.


Acetylcholinesterase Inhibitors: Use of huperzine A along with the acetylcholinesterase inhibitors donepezil or tacrine may produce additive effects, including additive adverse effects. Other acetylcholinesterase inhibitors include neostigmine, physostigmine and pyridostigmine, and use of these agents along with huperzine A may produce additive effects, including additive adverse effects.

Cholinergic Drugs: Use of huperzine A along with cholinergic drugs, such as bethanechol, may produce additive effects, including additive adverse effects.


Use of huperzine A with choline, phosphatidylcholine, CDP-choline and L-alpha-glycerylphosphorylcholine hypothetically might produce additive effects, including additive adverse effects.


There are no reports of overdosage with huperzine A.


There are various forms of huperzine A available, including extracts of Huperzia serrata, natural (-)-huperzine A and synthetic racemic (±)-huperzine A. Natural (-)-huperzine A is approximately three times more potent than the synthetic racemic mixture. The doses of natural (-)-huperzine A used in clinical studies ranged from 60 micrograms to 200 micrograms daily. Huperzine A should only be used with a physician's recommendation and monitoring.


Capsules — 50 mcg

Tablets — 50 mcg


Cheng DH, Tang XC. Comparative studies of huperzine A, E-2020 and tacrine on behavior and cholinesterase activities. Pharmacol Biochem Behav. 1998; 60:377-386.

Cheng DH, Ren H, Tang XC. Huperzine A, a novel promising acetylcholinesterase inhibitor. Neuroreport. 1996; 8:97-101.

Quian BC, Wang M, Zhou ZF, et al. Pharmacokinetics of tablet huperzine A in six volunteers. Chung Kuo Yao Li Hsueh Pao. 1995; 16:396-398.

Tang XC, Kindel GH, Kozikowski AP, Hanin I. Comparison of the effects of natural and synthetic huperzine A on rat brain cholinergic function in vitro and in vivo. J Ethnopharmacol. 1994; 44:147-155.

Xiong ZQ, Tang XC. Effect of huperzine A, a novel acetylcholinesterase inhibitor, on radial maze performance in rats. Pharmacol Biochem Behav. 1995; 51:415-419.

Xu SS, Gao ZX, Weng Z, et al. Efficacy of tablet huperzine-A on memory, cognition and behavior in Alzheimer's disease. Chung Kuo Yao Li Hsueh Pao. 1995; 16:391-395.

Ye JW, Cai JX, Wang LM, Tang XC. Improving effects of huperzine A on spatial working memory in aged monkeys and young adult monkeys with experimental cognitive impairment. J Pharmacol Exp Ther. 1999; 288:814-819.

Zhang RW, Tang XC, Han YY, et al. Drug evaluation of huperzine A in the treatment of senile memory disorders. [Article in Chinese] Chung Kuo Yao Li Hsueh Pao. 1991; 12:250-252.

Tuesday, July 06, 2004

Treasury Inflation Protected Securities (TIPS)

Treasury Inflation-Protected Securities, often called TIPS, are government issued securities whose value is linked to the inflation rate.

To read more on this go to the All American Investor: Treasury Inflation Protected Securities (TIPS)

Wednesday, June 30, 2004

Instant-messaging virus costs a man his job

A businessman whose computer had been infected by a virus found that his entire buddy list had been sent a record of all his IM conversations, said Derek O'Carroll, managing director of IM software vendor IMLogic on Tuesday.

Read this and more at IMFrame Instant Message News

Sunday, June 20, 2004

Inflation: CPI Breaks Secular Downtrend

Today's CPI report shows the annual rate of change in the CPI at 3.1%. This breaks the down trend which has been in place since rates last peaked in late 1990. The down trend in Core inflation remains intact... By Gibbons Burke


Read this and more investment stories at All American Investor

Monday, June 14, 2004

Inflation on the Horizon?

I am old enough that I lived through the big inflation in the late 70's. And right now it appears to me that we are embarking down a similar road.

The thing that surprises me most is that most analysts I read and see on CNBC say the same thing, "inflation is not a problem." They must not do any of their own shopping.

Read the Entire Article

Tuesday, May 25, 2004

Is gold's gut check over?

An interesting thought provoking article on CBS Marketwatch. You need a subscription to get the news--its free and worth the price.

Thursday, May 20, 2004

Welcome to Willow Street

Willow street is a place where people come to post and comment on issues currently on their mind. This is an any topic goes weblog.

Please refrain from "foul language" and personal attacks. Other than that, fire away.

If you would like to be authorized to post comments to this weblog email

We are always looking for bright, irreverant people that have interesting thoughts to share.